loi submission deadline: thursday, november 26, 2015 at 4:00 pm (eastern)

canet’s strategic research grants are intended to support small and large scale multidisciplinary multi-sectoral research projects that are presented in the context of a program of research that is aligned with the strategic priorities of the network.

this program is designed to support industry-partnered research projects that are aligned with the network’s strategic priorities. up to $200,000 per year for three years is available for projects that include partner cash and in-kind contributions of 4:1 of which at least 75% must be cash.

click here for information about the eligibility and application requirements.

request for proposals - “longitudinal study on the mental health of veterans during military to civilian transition”

veterans affairs canada requires a longitudinal qualitative study to better understand the mental health and well-being of canadian armed forces (caf) members/veterans, the determinants of mental health and well-being and the effectiveness of supports during the peri-release period of military to civilian transition (mct). the objective of this work is to enhance the mental health and well-being of caf veterans during mct to facilitate an optimal transition to civilian life.

the canadian institute for military and veteran health research (cimvhr) has entered into partnership with the government of canada to procure research and development services related to the mental, social and physical wellbeing of active military members, veterans and their families. cimvhr is seeking notices of interest from qualified researchers or a research team to enter into a contract with cimvhr to produce this work.

the weston brain institute is delighted to launch our transformational research 2016 program to fund high-potential translational research projects with excellent preliminary data. additional information about the program can be found on our website.

goal:

provide funding for preclinical translational research that will accelerate the development of therapeutics for neurodegenerative diseases of aging.

funding:

a maximum of $1,500,000 over up to 3 years.

eligibility:

researchers at or above the level of assistant professor or equivalent are eligible to apply as the principal applicant. collaborators must be at the post-doctoral level or above.

disease scope:

all the institute’s neurodegenerative diseases of aging are covered by this program (see funding overview) with the exception of amyotrophic lateral sclerosis (als).

new for 2016: projects focused on als should be submitted to the als-focused program scheduled to launch in spring 2016.

development scope:

development of a therapeutic and/or a tool that helps to accelerate the development of therapeutics for neurodegenerative diseases of aging.

dates:

program information session:

tuesday, november 17^th 2015, 1:00pm est

letter of intent deadline:

thursday, january 14^th 2016, 2:00pm est

submission of the letter of intent is done through the institute’s online grant management system here.

the weston brain institute will be holding an online program information session for this funding opportunity on tuesday, november 17^that 1:00 pm est. this session is intended to provide you with comprehensive information on the application process and to provide an opportunity to ask questions.  

to register for the tr16 information session and receive the dial in details as well as submit any questions you may have in advance, please click here.

the institute welcomes inquiries about our funding programs to neuro@weston.ca or 416-935-4056.

the ministry of natural resources and forestry is now accepting applications for the 2016-2017 species at risk research fund for ontario (sarrfo).

the sarrfo supports the protection and recovery of species at risk by funding high quality scientific research that addresses key threats, knowledge gaps, and informs better species protection and management.

all applicants are to carefully read the attached sarrfo guidelines before completing and submitting an application. 

priorities have been identified for the 2016-17 funding year and are outlined within the guidelines. applications that address any of the 2016-17 priorities will be considered for funding before subsequent applications.

defense health program
neurotoxin exposure treatment parkinson's research program
funding opportunities for fiscal year 2015

the fiscal year 2015 (fy15) defense appropriations act provides $16 million (m) to the department of defense neurotoxin exposure treatment parkinson's research (netpr) program to provide support for research of exceptional scientific merit leading to an understanding of the cause, prevention, and treatment of the loss of dopaminergic neurons in the substantia nigra that result in parkinson's disease (pd). applications to the fy15 netpr program will be solicited by the u.s. army medical research acquisition activity (usamraa). the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

http://cdmrp.army.mil/funding/netpr.shtml

the mission of the netpr program is to:

·         identify surrogate markers of pd,

·         correlate distinctive clinical features with specific clusters of these markers, and

·         develop interventions in bio-molecular pathways that link markers and expressed clinical features in order to prevent or halt progression of the disease or improve the quality of life for pd patients.

depression research award – letter of intent due december 2, 2015

·         independent investigators at or above the level of associate professor (or equivalent).

• supports research efforts that will make significant advancements in the understanding of serotonergic and non-serotonergic molecular pathways identified with depression and associated biologic phenomena that link the pathways to other risk factors in the development and progression of pd.
• research supported by this award should lead to the development of new treatments or improvement of current treatments for depression, specifically in individuals with or at risk for pd.
• preliminary data are required.
• this funding opportunity is specifically focused on the netpr programs areas of emphasis on depression as a risk factor and/or co-morbidity in pd.
• innovative applications not focused on the areas of emphasis noted above are acceptable if specifically related to development or progression of depression as a non-motor manifestation of pd and/or is clearly linked to depression as a risk factor for initiation or progression of pd.
• submission of a letter of intent (loi) is required prior to full application submission.

·         clinical trials are not allowed.

·         the direct costs allowed and periods of performance are shown below.

• anticipation is that budgets will not exceed $1,500,000 in direct costs.

·         period of performance not to exceed 3 years.

career progression award – letter of intent due december 2, 2015

·         independent investigators at or below the level of assistant professor (or equivalent).

·         never received an r01 grant from the national institutes of health (nih).

• supports independent, early-career investigators who have innovative, high-impact ideas or new technologies applicable to pd research and/or patient care.
• provides funding and experience necessary for productive career progression at the forefront of research specifically on non-motor aspects of pd.
• preliminary data are required.
• this funding opportunity is specifically focused on the netpr programs areas of emphasis for non-motor manifestations in pd (e.g., cognitive impairment, depression autonomic dysfunction, and sleep disturbance).
• innovative applications not focused on the areas of emphasis noted above are acceptable, provided the application addresses the development of progression of one or more non-motor manifestations of pd and provides a strong rationale for relevance to the mission of the netpr program.
• submission of a letter of intent is required prior to full application submission.

·         clinical trials are not allowed.

·         the direct costs allowed and periods of performance are shown below.

• anticipation is that budgets will not exceed $250,000 in direct costs.

·         period of performance not to exceed 2 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

applications must be submitted through the federal government's single-entry portal, grants.gov. requests for email notification of the program announcements release may be sent to help@ebrap.org. for more information about the netpr program or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

fy15 extremity regeneration technology/therapeutic development award

the fy15 jpc-8/crmrp erttda is intended to support the translation of promising preclinical findings into products focused on extremity regeneration. the focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and regenerative medicine technologies for the treatment of trauma-induced damage. all products in development should be responsive to the health care needs of military service members, veterans, and other military health system beneficiaries, as well as the general public. all applications must specifically and clearly address the military relevance of the proposed research.

fy15 extremity regeneration intervention

the fy15 jpc-8/crmrp eri is intended to support phase i, ii, or pivotal clinical trial phase development projects focused on extremity regeneration. the focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and regenerative medicine technologies for the treatment of trauma-induced damage. all clinical trials must be responsive to the health care needs of military service members and veterans, as well as the general public. all proposals/applications must specifically and clearly address the military relevance of the proposed research.

objectives

the specific objective of this funding opportunity is to support the conduct of rapid turn-around, time-sensitive, cross-jurisdictional research studies that align with the pan-canadian network’s quick strike research priorities (listed in the relevant research areas).

relevant research areas

quick strike research priorities:

priorities have been determined in consultation with the member networks and partners over the course of the summer and fall of 2014. a high-level summary of priorities is found below. full descriptions of all relevant research areas can be found in a separate document that has been shared with the member networks. for information please contact spor-srap@cihr-irsc.gc.ca.  applicants must demonstrate how the proposed quick strike research project responds to one or more of the following priorities:

• defining complex needs, identifying individuals with complex health and social needs and understanding their needs - priority populations include individuals with chronic conditions, mental health and addiction challenges, youth with chronic conditions who are transitioning to adult care, high users of the healthcare system, and individuals not attached to a primary care team;
• innovation in integrated service delivery models that meet the needs of individuals with complex needs and that are focused on prevention, housing, community care and individuals with multi-morbidity and chronic conditions;
• ehealth innovations that improve person-centered, appropriate and integrated care;
• integrating health promotion/disease prevention in care delivery models to prevent future needs for complex care;
• patient’s role in maintaining their health: patient literacy;
• supporting healthy aging and the needs of older adults through primary and integrated models of care;
• outcome/value-based funding models that incentivize integration; or
• understanding health outcomes that should be prioritized.